Immix Biopharma Files Q1 2025 10-Q
Ticker: IMMX · Form: 10-Q · Filed: May 8, 2025 · CIK: 1873835
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Immix Biopharma dropped its Q1 2025 10-Q. Financials look steady.
AI Summary
Immix Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported financial data for the first quarter of 2025. Key financial statement items like common stock, additional paid-in capital, and retained earnings were detailed for the periods ending March 31, 2025, December 31, 2024, and December 31, 2023.
Why It Matters
This filing provides investors with the latest financial snapshot of Immix Biopharma, crucial for understanding its financial health and performance in early 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Immix Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this summary but are typical for the sector.
Key Numbers
- Q1 2025 — Reporting Period (First quarter financial results)
- 20250331 — Period End Date (Latest financial data reported)
Key Players & Entities
- Immix Biopharma, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- 2834 (other) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary business of Immix Biopharma, Inc.?
Immix Biopharma, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code 2834.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 8, 2025.
What are some of the key financial statement components reported?
Key financial statement components reported include Common Stock, Additional Paid-In Capital, Accumulated Other Comprehensive Income, Retained Earnings, Treasury Stock Common, and Noncontrolling Interest.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Immix Biopharma, Inc. (IMMX).